These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 34865874)

  • 1. Human papillomavirus vaccines effectiveness to prevent genital warts: A population-based study using health system integrated databases, 2009-2017.
    Muñoz-Quiles C; López-Lacort M; Díez-Domingo J; Rodrigo-Casares V; Orrico-Sánchez A
    Vaccine; 2022 Jan; 40(2):316-324. PubMed ID: 34865874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of HPV vaccines against genital warts in women from Valencia, Spain.
    Navarro-Illana E; López-Lacort M; Navarro-Illana P; Vilata JJ; Diez-Domingo J
    Vaccine; 2017 Jun; 35(25):3342-3346. PubMed ID: 28499554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study.
    Leval A; Herweijer E; Ploner A; Eloranta S; Fridman Simard J; Dillner J; Young C; Netterlid E; Sparén P; Arnheim-Dahlström L
    J Natl Cancer Inst; 2013 Apr; 105(7):469-74. PubMed ID: 23486550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.
    Herweijer E; Leval A; Ploner A; Eloranta S; Simard JF; Dillner J; Netterlid E; Sparén P; Arnheim-Dahlström L
    JAMA; 2014 Feb; 311(6):597-603. PubMed ID: 24519299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort Study.
    Dominiak-Felden G; Gobbo C; Simondon F
    PLoS One; 2015; 10(7):e0132404. PubMed ID: 26147096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada.
    Kohli M; Lawrence D; Haig J; Anonychuk A; Demarteau N
    BMC Public Health; 2012 Oct; 12():872. PubMed ID: 23061913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2,2 million individuals.
    Nygård S; Nygård M; Orumaa M; Hansen BT
    Vaccine; 2023 Aug; 41(37):5469-5476. PubMed ID: 37516572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The quadrivalent HPV vaccine is protective against genital warts: a meta-analysis.
    Lukács A; Máté Z; Farkas N; Mikó A; Tenk J; Hegyi P; Németh B; Czumbel LM; Wuttapon S; Kiss I; Gyöngyi Z; Varga G; Rumbus Z; Szabó A
    BMC Public Health; 2020 May; 20(1):691. PubMed ID: 32460747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
    Westra TA; Stirbu-Wagner I; Dorsman S; Tutuhatunewa ED; de Vrij EL; Nijman HW; Daemen T; Wilschut JC; Postma MJ
    BMC Infect Dis; 2013 Feb; 13():75. PubMed ID: 23390964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HPV vaccination leads to decrease of anogenital warts and precancerous lesions of the cervix uteri in young women with low vaccination rates: a retrospective cohort analysis.
    Osmani V; Fett S; Tauscher M; Donnachie E; Schneider A; Klug SJ
    BMC Cancer; 2022 Dec; 22(1):1293. PubMed ID: 36494790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of different human papillomavirus vaccines in Singapore.
    Lee VJ; Tay SK; Teoh YL; Tok MY
    BMC Public Health; 2011 Mar; 11():203. PubMed ID: 21453537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-Dose Human Papillomavirus Vaccination and the Risk of Genital Warts: A Danish Nationwide Population-based Study.
    Baandrup L; Dehlendorff C; Kjaer SK
    Clin Infect Dis; 2021 Nov; 73(9):e3220-e3226. PubMed ID: 33048118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model.
    Bardach AE; Garay OU; Calderón M; Pichón-Riviére A; Augustovski F; Martí SG; Cortiñas P; Gonzalez M; Naranjo LT; Gomez JA; Caporale JE
    BMC Public Health; 2017 Feb; 17(1):152. PubMed ID: 28148228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
    Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
    Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors.
    Woestenberg PJ; King AJ; van der Sande MA; Donken R; Leussink S; van der Klis FR; Hoebe CJ; Bogaards JA; van Benthem BH; ;
    J Infect; 2017 Apr; 74(4):393-400. PubMed ID: 28126492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data.
    Donovan B; Franklin N; Guy R; Grulich AE; Regan DG; Ali H; Wand H; Fairley CK
    Lancet Infect Dis; 2011 Jan; 11(1):39-44. PubMed ID: 21067976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose-Related Differences in Effectiveness of Human Papillomavirus Vaccination Against Genital Warts: A Nationwide Study of 550,000 Young Girls.
    Blomberg M; Dehlendorff C; Sand C; Kjaer SK
    Clin Infect Dis; 2015 Sep; 61(5):676-82. PubMed ID: 25944340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of quadrivalent human papillomavirus vaccine on genital warts in an opportunistic vaccination structure.
    Lurie S; Mizrachi Y; Chodick G; Katz R; Schejter E
    Gynecol Oncol; 2017 Aug; 146(2):299-304. PubMed ID: 28602548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
    McCormack PL; Joura EA
    BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential impact of the human papillomavirus vaccine on the incidence proportion of genital warts in French women (EFFICAE study): a multicentric prospective observational study.
    Judlin P; Jacquard AC; Carcopino X; Aubin F; Dahlab A; Mistretta F; Not D; Boelle PY; Aynaud O; Soubeyrand B
    Sex Health; 2016 Feb; 13(1):49-54. PubMed ID: 26567557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.